Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).

July 25, 2025

Vol.51 No.29

In Brief

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

Geraldine O’Sullivan Coyne was appointed system head of Northwell and principal investigator for the START Center for Cancer Research, a newly established unit at the health system aimed at bringing innovative early stage clinical trials to patients in a community-based cancer center.

July 25, 2025

Vol.51 No.29

In Brief

SITC Forward Fund announces 2025 fellowship recipients

The Society for Immunotherapy of Cancer Forward Fund announced the recipients of the 2025 SITC Fellowships.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Secretogranin 2 binds LILRB4 resulting in immunosuppression, UT Southwestern study suggests

Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body’s natural defenses.

July 25, 2025

Vol.51 No.29

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

YOU MAY BE INTERESTED IN

City of Hope brings evidence-based approaches to integrative oncology

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

SITC Forward Fund announces 2025 fellowship recipients

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

Secretogranin 2 binds LILRB4 resulting in immunosuppression, UT Southwestern study suggests

Renew today!

Subscriber content

Never miss an issue!

Login